A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.
Gene therapy represents an alternative and promising anti-HIV modality to highly active antiretroviral therapy. It involves the introduction of a protective gene into a cell, thereby conferring protection against HIV. While clinical trials to date have delivered gene therapy to CD4+T cells or to CD3...
Main Authors: | Borislav Savkovic, James Nichols, Donald Birkett, Tanya Applegate, Scott Ledger, Geoff Symonds, John M Murray |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-06-01
|
Series: | PLoS Computational Biology |
Online Access: | http://europepmc.org/articles/PMC4063676?pdf=render |
Similar Items
-
23 Knockdown of CCR5 expression in antigen-specific cytotoxic CD4 T cells
by: John Zaunders, et al.
Published: (2017-07-01) -
In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy
by: Mcintyre Glen, et al.
Published: (2010-10-01) -
Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
by: Borislav Savkovic, et al.
Published: (2012-01-01) -
Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells.
by: Michelle Millington, et al.
Published: (2009-07-01) -
CD44, hyaluronan, the hematopoietic stem cell and leukemia-initiating cells
by: Margot eZoeller
Published: (2015-05-01)